司帕沙星与氧氟沙星治疗老年呼吸道细菌感染

Comparative Study on Sparfloxacin and Ofloxacin in the Treatment of Respiratory TractBacterial Infections in the Senile Patients

目的:对照研究司帕沙星(SPFX)与氧氟沙星(OFLX)治疗老年患者呼吸道细菌感染(RTBI)的临床疗效及安全性。方法:将120例呼吸道细菌感染的老年患者随机分入试验(T)组和对照(C)组。试验组给予司帕沙星口服300mg,1次/d,对照组给予氧氟沙星口服200mg,2次/d。疗程均为7～10d。结果:试验组的综合疗效显著优于对照组(P<0.01),试验组痊愈率为71.7%,有效率为95.0%,均显著高于对照组(均P<0.05);试验组不良反应为3.33%,对照组不良反应为6.67%。结论:司帕沙星治疗老年患者呼吸道细菌感染疗效肯定、安全。

Objective: To compare the efficacy and safety of Sparfloxacin (SPFX) and Ofloxacin (OFLX) in the treatment of respiratory tract bacterial infections (RTBI) in the senile patients. Methods: One hundred and twenty patients with RTBI were randomly divided into two groups Which were treated with SPFX 300 mg, qd, po. for 7-10 d in test group (T) and Ofloxacin 200 mg, bid, po. for 7-10 d in control group (C). Results: The comprehensive efficacy in T group was significantly higher than that in C group (P < 0.0l). The recovery rate (71.7%) and the effective rate (95.0%) of T group were significantly higher than that those of C group (P < 0.05). The side effect rates of T and C groups were 3.33% and 6.67% respectively. Conclusion: SPFX is very effective and safe in the treatment of RTBI in the senile patients.